Studies: Alzheimer drug may stabilize brain plaque (Update)

September 11, 2012 by Marilynn Marchione

An experimental drug that failed to stop mental decline in Alzheimer's patients in the U.S. and Canada also showed some potential benefit in slowing brain plaque, fuller results of two major studies show.

Some patients on the drug had stable levels of brain plaque and less evidence of nerve damage compared to others who were given a dummy treatment, researchers reported Tuesday in Sweden.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

The drug, called bapineuzumab, is made by Pfizer Inc. and Johnson & Johnson. The new results suggest it might work if given earlier in the course of the disease, before so much damage and memory loss have occurred that it might not be possible to reverse, experts say.

"We're very disappointed that we were not able to come up with a treatment to provide to our dementia patients in the near term," said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston and leader of one of the studies.

But brain imaging and spinal fluid tests are "very encouraging" and suggest "that we were doing something to the biology of the disease" by giving the drug, she said.

"We've got a path forward" now to test it in people with mild mental impairment or those who show plaque on brain imaging but have not yet developed symptoms of dementia, Sperling said.

Of people with mild cognitive impairment, about 15 to 20 percent a year will develop Alzheimer's disease.

Bapineuzumab is designed to attach to and help clear amyloid, the stuff that makes up the sticky plaque that clogs patients' brains, harming nerve cells and impairing memory and thought. Doctors don't know whether amyloid is a cause or just a symptom of Alzheimer's, but many companies are testing drugs to try to remove it.

Two studies of more than 1,000 patients each in the United States and Canada tested bapineuzumab in people with mild to moderate Alzheimer's. Sperling's study involved people with a gene that raises the risk of developing the disease. Dr. Stephen Salloway, a neurologist at Brown Medical School, led the other study of people without the gene.

Both researchers have consulted for the companies that make the drug and presented results Tuesday at a neurology conference in Sweden.

The companies previously announced that the 18-month studies failed to meet their main goal of slowing mental decline or improving activities of daily living.

However, brain imaging on a subset of patients in Sperling's study found 9 percent less amyloid in those on bapineuzumab compared to those on a dummy treatment. The drug group had stable levels while the others developed more plaque. Spinal fluid tests on some participants also showed the drug group had less of another substance that is released when nerve cells are damaged.

"I found that very encouraging, that we were doing something to the biology of the disease. We're having an impact on nerve cell injury," Sperling said.

There were potential safety concerns. There were 15 deaths among the 673 in bapineuzumab group versus only five among the 448 in the placebo group. Six of the deaths in the drug group were from various forms of cancer. But a wider review of thousands of patients in multiple studies of bapineuzumab found that cancer was not more common among those on the drug.

The cancer deaths "were wide and varied, and they weren't a specific type of cancer, so that's not raising any red flags," said an independent expert, Dr. Maria Carrillo, a senior scientist at the Alzheimer's Association.

Salloway's study produced less evidence of benefit. Too few participants had brain imaging to make definitive conclusions about amyloid, and there was just a trend toward less of the nerve-damage substance in the group receiving the higher of two doses tested.

Bapineuzumab is given as periodic intravenous infusions, and the companies have said they are stopping development of that form but continuing to test a version that can be given as a shot.

More results on this drug and a similar one—Eli Lilly & Co.'s solanezumab—will be presented at a conference in Boston next month. Lilly recently announced that combined results of two large studies of solanezumab suggested some benefit on cognition.

Explore further: Pfizer and J&J end development of Alzheimer's drug

shares

Related Stories

Pfizer and J&J end development of Alzheimer's drug

August 6, 2012
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

Alzheimer's drug fails in 1 study, 2nd continues (Update)

July 23, 2012
(AP) — A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. ...

Small study: Drug may help stabilize Alzheimer's

July 17, 2012
For the first time, researchers are reporting that a treatment might help stabilize Alzheimer's disease for as much as three years, although the evidence is weak and found in only four patients.

Key results coming on 3 drugs against Alzheimer's

July 11, 2012
We're about to find out if there will be a way any time soon to slow the course of Alzheimer's disease. Results are due within a month or so from key studies of two drugs that aim to clear the sticky plaque gumming up patients' ...

Study reveals link between high cholesterol and Alzheimer's disease

September 12, 2011
People with high cholesterol may have a higher risk of developing Alzheimer's disease, according to a study published in the September 13, 2011, issue of Neurology, the medical journal of the American Academy of Neurology.

Recommended for you

Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms

August 17, 2017
Cedars-Sinai neuroscience investigators have found that Alzheimer's disease affects the retina—the back of the eye—similarly to the way it affects the brain. The study also revealed that an investigational, noninvasive ...

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

Alzheimer's risk linked to energy shortage in brain's immune cells

August 14, 2017
People with specific mutations in the gene TREM2 are three times more likely to develop Alzheimer's disease than those who carry more common variants of the gene. But until now, scientists had no explanation for the link.

Scientists reveal role for lysosome transport in Alzheimer's disease progression

August 7, 2017
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. The study, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.